ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription
Ielizaveta Gorodetska, Anne Offermann, Jakob Püschel, Vasyl Lukiyanchuk, Diana Gaete, Anastasia Kurzyukova, Vera Freytag, Marie‐Therese Haider, Christina S. Fjeldbo, Simona Di Gaetano, Franziska Maria Schwarz, Shivaprasad G. Patil, Angelika Borkowetz, Holger H.H. Erb, Aria Baniahmad, Jovan Mircetic, Heidi Lyng, Steffen Löck, Annett Linge, Tobias Lange, Franziska Knopf, Ben Wielockx, Mechthild Krause, Sven Perner, Anna Dubrovska
Abstract
This report provides the first evidence that ALDH1A1 and PLK3 could serve as biomarkers to predict metastatic dissemination and radiotherapy resistance in patients with prostate cancer and could be potential therapeutic targets to eliminate metastasis-initiating and radioresistant tumor cell populations.
Topics & Concepts
Prostate cancerRadioresistanceCancer stem cellCancer researchMetastasisBiologyProstateCancerTumor progressionOncologyPathologyMedicineInternal medicineRadiation therapyProstate Cancer Treatment and ResearchCancer, Lipids, and MetabolismCancer, Hypoxia, and Metabolism